NO20042410L - Sammensetning som omfatter angiopoietinliknende protein 3, ANGPTL3 og fremgangsmate til anvendelse av samme - Google Patents

Sammensetning som omfatter angiopoietinliknende protein 3, ANGPTL3 og fremgangsmate til anvendelse av samme

Info

Publication number
NO20042410L
NO20042410L NO20042410A NO20042410A NO20042410L NO 20042410 L NO20042410 L NO 20042410L NO 20042410 A NO20042410 A NO 20042410A NO 20042410 A NO20042410 A NO 20042410A NO 20042410 L NO20042410 L NO 20042410L
Authority
NO
Norway
Prior art keywords
angptl3
angiopoietin
protein
composition
same
Prior art date
Application number
NO20042410A
Other languages
English (en)
Other versions
NO336021B1 (no
Inventor
Napoleone Ferrara
Hans-Peter Gerber
Joe Kowalski
Maria Teresa Pisabarro
Daniel Eric Sherman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of NO20042410L publication Critical patent/NO20042410L/no
Publication of NO336021B1 publication Critical patent/NO336021B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
NO20042410A 2001-11-16 2004-06-09 Anvendelse av en antagonist av Angptl3 til fremstilling av et medikament for behandling eller forebygging av vevsskade forbundet med en inflammatorisk leversykdom, og en antagonist av Angptl3 for nevnte anvendelse. NO336021B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33242901P 2001-11-16 2001-11-16
PCT/US2002/036865 WO2003044172A2 (en) 2001-11-16 2002-11-13 Composition comprising and method of using angiopoietin-like protein 3 angptl3

Publications (2)

Publication Number Publication Date
NO20042410L true NO20042410L (no) 2004-06-09
NO336021B1 NO336021B1 (no) 2015-04-20

Family

ID=23298191

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042410A NO336021B1 (no) 2001-11-16 2004-06-09 Anvendelse av en antagonist av Angptl3 til fremstilling av et medikament for behandling eller forebygging av vevsskade forbundet med en inflammatorisk leversykdom, og en antagonist av Angptl3 for nevnte anvendelse.

Country Status (14)

Country Link
US (3) US7267819B2 (no)
EP (1) EP1451578B1 (no)
JP (2) JP5105696B2 (no)
KR (2) KR101012904B1 (no)
CN (2) CN1615440A (no)
AU (1) AU2002348286B2 (no)
CA (1) CA2464542C (no)
ES (1) ES2429034T3 (no)
IL (2) IL161542A0 (no)
MX (1) MXPA04004609A (no)
NO (1) NO336021B1 (no)
NZ (1) NZ532852A (no)
WO (1) WO2003044172A2 (no)
ZA (1) ZA200403070B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN1615440A (zh) 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法
AU2004266043B2 (en) * 2003-08-21 2007-09-20 Duchesnay Inc. Micronutrient supplement
EP1771474B1 (en) 2004-07-20 2010-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
AU2005269758B2 (en) 2004-07-20 2011-11-03 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
WO2007038407A2 (en) 2005-09-23 2007-04-05 The Regents Of The University Of California Compositions and methods for treating nervous system disorders
KR101503937B1 (ko) * 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Ａｎｇｐｔｌ３ 에 대한 단일클론 항체
EP2265638A1 (en) * 2008-04-14 2010-12-29 Hadasit Medical Research Services And Development Ltd. Stable cell binding chimeric peptides
CN101852805B (zh) * 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
MA33423B1 (fr) 2009-07-14 2012-07-03 Scripps Research Inst Différentiation de cellules souches mésenchymateuses
CN106146591B (zh) * 2010-01-08 2020-07-31 Ionis制药公司 血管生成素样3表达的调节
AU2015200969A1 (en) * 2010-01-08 2015-03-19 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
CN102687027B (zh) * 2010-02-02 2016-05-25 阿利桑那卅评议会 用于测序聚合物的受控的隧道间隙设备
EP2668499A4 (en) * 2011-01-29 2015-05-27 Astute Medical Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
JO3412B1 (ar) * 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
US9403877B2 (en) 2012-01-24 2016-08-02 Inter-K Pty Limited Peptide agents for cancer therapy
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (ar) 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
CN104062432B (zh) * 2013-03-22 2016-01-20 中山大学 ang2在制备ECTC血管类型肝癌诊断试剂及治疗药物中的应用
AU2014259759B2 (en) 2013-05-01 2020-06-18 Ionis Pharmaceuticals, Inc. Compositions and methods
MX2016008462A (es) 2013-12-24 2016-10-12 Ionis Pharmaceuticals Inc Modulacion de la expresion similar a la angiopoyetina tipo 3.
BR122020024443B1 (pt) 2014-05-01 2022-02-22 Ionis Pharmaceuticals, Inc Composto e composição farmacêutica para modulação da expressão de angptl3
CN105021827B (zh) * 2015-07-17 2016-09-28 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
MX2018005277A (es) 2015-11-06 2018-08-01 Ionis Pharmaceuticals Inc Modular la expresion de apolipoproteina (a).
KR102487839B1 (ko) * 2016-02-04 2023-01-12 리제너론 파마슈티칼스 인코포레이티드 조작된 angptl8 유전자를 갖는 비인간 동물
CN117701562A (zh) * 2017-09-14 2024-03-15 箭头药业股份有限公司 用于抑制血管生成素-样3(ANGPTL3)的表达的RNAi剂和组合物以及使用方法
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020099482A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
CN111122872B (zh) * 2019-11-20 2023-01-20 中山大学附属第一医院 血管生成素样蛋白7在心力衰竭预后评估中的应用
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
WO2022187353A1 (en) * 2021-03-05 2022-09-09 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
CN114934021B (zh) * 2022-04-21 2023-08-08 复旦大学附属儿科医院 一种Angptl3敲除的鼠永生化足细胞系及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
EP0917878A4 (en) 1997-02-26 2004-05-19 Toray Industries REMEDIES FOR HEPATITIS
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
CA2332109A1 (en) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
KR100553300B1 (ko) * 1999-03-08 2006-02-20 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
CN1615440A (zh) 2001-11-16 2005-05-11 杰南技术公司 含有血管生成素－样蛋白质3angptl3的组合物及其使用方法

Also Published As

Publication number Publication date
NO336021B1 (no) 2015-04-20
US20030215451A1 (en) 2003-11-20
KR20050044485A (ko) 2005-05-12
NZ532852A (en) 2006-08-31
KR101012904B1 (ko) 2011-02-08
ZA200403070B (en) 2005-06-29
US7267819B2 (en) 2007-09-11
MXPA04004609A (es) 2004-08-12
EP1451578A2 (en) 2004-09-01
JP2010100624A (ja) 2010-05-06
IL161542A0 (en) 2004-09-27
IL203894A (en) 2013-09-30
AU2002348286B2 (en) 2008-04-03
CN1615440A (zh) 2005-05-11
ES2429034T3 (es) 2013-11-12
KR20100029861A (ko) 2010-03-17
EP1451578B1 (en) 2013-08-21
US8541376B2 (en) 2013-09-24
CA2464542A1 (en) 2003-05-30
AU2002348286A1 (en) 2003-06-10
EP1451578A4 (en) 2006-02-01
CN101905024A (zh) 2010-12-08
US20070134250A1 (en) 2007-06-14
JP5105696B2 (ja) 2012-12-26
CA2464542C (en) 2015-01-20
US20090098117A1 (en) 2009-04-16
WO2003044172A2 (en) 2003-05-30
WO2003044172B1 (en) 2004-03-18
JP2005521643A (ja) 2005-07-21
WO2003044172A3 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
NO20042410L (no) Sammensetning som omfatter angiopoietinliknende protein 3, ANGPTL3 og fremgangsmate til anvendelse av samme
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK0965578T3 (da) Hidtil ukendt triglycerik og præparat, som omfatter dette
MXPA03006884A (es) Formulacion farmaceutica.
DE60202270D1 (de) 4,5-dihydro-1h-pyrazolderivate mit cb1-antagonistischer wirkung
MXPA03007827A (es) Metodo y composicion para la coloracion permanente gradual de cabello.
MXPA03007641A (es) Formulacion farmaceutica.
CY2009017I2 (el) Μεθοδος για την παρασκευη 10, 11-διυδρο-10-υδροξυ-5η-διβενζο/β,f/αζεπινο-5-καρβοξαμιδιου και 10,11-διυδρο-10-οξο-5η-διβενζο/β,f/αζεπινο-5-καρβοξαμιδιου
NO20010326L (no) FSH og FSH-variantformuleringer, produkter og fremgangsmÕter
BR0209195B1 (pt) aquecedor para pirólise e método para operar o mesmo.
NO20012727D0 (no) 3,4,5-trisubstituerte arylnitronforbindelser og farmasöytiske sammensetninger som inneholder samme
ZA200402729B (en) Pharmaceutical formulation comprising (R) -bicalutamide.
MA26666A1 (fr) Antioxide, composition antiproliferee, y compris carnitine et carotenoide.
DK1363490T3 (da) Agrokemiske præparater
NO984444D0 (no) Benzothiofener, formuleringer som inneholder de samme, og fremgangsmÕter
DK0791591T3 (da) Benzothiophener, formuleringer indeholdende samme og fremgangsmåder til deres fremstilling
ATE369137T1 (de) Lyophilisierte formulierung enthaltend olanzapin
IL162310A0 (en) 3,4-Dihydro-1h-isoquinoloin-2-yl-derivatives
DK1053224T3 (da) Biphenylfulfonylcyanamider, fremgangsmåde til fremstilling deraf og anvendelse deraf som lægemiddel
EP1389204A4 (en) NEW SULPHONAMIDE DERIVATIVES, THEIR INTERMEDIATES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE COMPOUNDS
DE50107204D1 (de) 8beta-substituierte-11beta-pentyl-und 11beta-hexyl-estra-1,3,5(10)-trienderivate
GB0217548D0 (en) Four human zinc-finger-containing proteins:MDZ3.MDZ4,MDZ7 and MDZ12
PT1408035E (pt) Metodo de preparacao de derivativos de 1.5-diaril-3-trifluorometilo-delta2-pirazolinas que sejam racemicos e enanciomericamente puros
DE60136966D1 (de) Pflanzenstärkendes mittel
MXPA03007242A (es) Delta-1-pirrolinas para control de pestes.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees